Effect of therapeutic immunization using Ad5/35 and MVA vectors on SIV infection of rhesus monkeys undergoing antiretroviral therapy.
D000256:Adenoviridae / Q000235:genetics; D000818:Animals; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D000914:Antibodies, Viral / Q000096:biosynthesis; D018791:CD4 Lymphocyte Count; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D003131:Combined Modality Therapy; D003602:Cytotoxicity, Immunologic; D005822:Genetic Vectors; D007111:Immunity, Cellular; D007114:Immunization; D018655:Lymphocyte Count; D008253:Macaca mulatta; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D018449:SAIDS Vaccines / Q000276:immunology / Q000627:therapeutic use*; D016097:Simian Acquired Immunodeficiency Syndrome / Q000276:immunology / Q000628:therapy* / Q000821:virology; D015302:Simian Immunodeficiency Virus / Q000276:immunology / Q000302:isolation & purification; D014613:Vaccines, Attenuated / Q000276:immunology / Q000627:therapeutic use; D014616:Vaccinia virus / Q000235:genetics; D019562:Viral Load
D019380:Anti-HIV Agents; D000914:Antibodies, Viral; D018449:SAIDS Vaccines; D014613:Vaccines, Attenuated